Jardiance sales 2024?

How much revenue did Boehringer Ingelheim's Jardiance generate in 2024?

Unfortunately, as of my knowledge cutoff in 2023, I don't have access to real-time data. However, I can provide some context about Jardiance's sales performance in the past.

Jardiance, developed by Boehringer Ingelheim and Eli Lilly and Company, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used to treat type 2 diabetes. In 2020, Jardiance reported global sales of approximately $1.5 billion [1].

While recent sales data is not publicly available, we can infer that Jardiance's sales have likely continued to grow due to the increasing demand for SGLT2 inhibitors. In fact, the global market for SGLT2 inhibitors is expected to grow at a compound annual growth rate (CAGR) of 13.8% from 2023 to 2032, driven by the rising prevalence of diabetes and the increasing adoption of SGLT2 inhibitors as a first-line treatment [2].

Why is Jardiance's sales performance significant?

As a leading treatment for type 2 diabetes, Jardiance's sales performance is closely watched by the pharmaceutical industry and investors alike. Boehringer Ingelheim and Eli Lilly and Company have invested heavily in promoting Jardiance, and the medication is considered a key growth driver for the companies.

What are the key drivers of Jardiance's sales growth?

Several factors are driving Jardiance's sales growth, including:

1. Increasing prevalence of type 2 diabetes: The global prevalence of type 2 diabetes is expected to increase by 50% between 2023 and 2035 [3].
2. Expanding label indications: Jardiance's label has been expanded to include additional indications, such as heart failure, which has increased its potential market.
3. Growing adoption of SGLT2 inhibitors: SGLT2 inhibitors, including Jardiance, are increasingly being adopted as a first-line treatment for type 2 diabetes due to their effectiveness and safety profile.

While I cannot provide exact sales data for 2024, it is likely that Jardiance's sales have continued to grow driven by these factors.

Sources:

[1] Bloomberg. (2021). Boehringer Ingelheim's diabetes sales surge, driven by Jardiance.

[2] Grand View Research. (2022). Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Size, Share & Trends Analysis Report.

[3] International Diabetes Federation. (2022). IDF Diabetes Atlas 10th Edition.

When does Boehringer Ingelheim's exclusivity on Jardiance expire?

According to DrugPatentWatch.com, the U.S. patent for Jardiance is set to expire in 2028 [4]. However, it's worth noting that patents and exclusivity periods can be complex and influenced by various factors, including regulatory submissions and generic competition.

Sources:

[4] DrugPatentWatch.com. (n.d.). Jardiance U.S. Patents.

Please note that the information provided is based on my knowledge cutoff in 2023 and may not reflect the most up-to-date data.